Cambridge, Mass., April 14, 2026 — GentiBio, a clinical stage biotechnology company advancing engineered regulatory T cell (Treg) therapies to treat autoimmune and inflammatory diseases, today announced it will present multiple seminars and posters at the 2026 American Association of Immunologists (AAI) Annual Meeting, taking place April 15–19.
GentiBio scientists will share new data highlighting advances across the company’s engineered Treg platform, including allogeneic, tissue targeted, and modular Treg approaches. These presentations build on GentiBio’s recent clinical progress, including dosing of the first participant in the POLARIS Phase 1 clinical trial evaluating GNTI 122, an engineered Treg therapy in development for Type 1 diabetes.
Oral Seminar Presentations
- Martina Sassone Corsi, Associate Director
“GNTI 932: A Targeted, Scalable, and Hypoimmune Allogeneic Engineered Treg Therapy for the Treatment of Inflammatory Bowel Disease”
Thursday, April 16 | 1:00 PM - Payam Zarin, Associate Director
“Allogeneic Tissue Tregs Improve Disease Outcome in Models of Acute Lung and Kidney Injury”
Friday, April 17 | 1:00 PM
Poster Presentations
- Nathan Zammit, Principal Scientist
“ST2 Enforces a ‘Repair Ready’ Treg Phenotype that Homes to and Ameliorates Neuroinflammation”
Thursday, April 16 | 11:30 AM - Maegan Hoover, Scientist II
“Modular Engineering of Tregs for the Treatment of Inflammatory and Autoimmune Diseases”
Saturday, April 18 | 11:30 AM - Victoria DeVault Nelson, Associate Director
“Comprehensive Biomarker Strategy to Monitor GNTI 122, an Engineered Regulatory T Cell Therapy in Clinical Development to Treat Type 1 Diabetes”
Saturday, April 18 | 2:30 PM - Christopher Moore, Director
“An Allogeneic CD19 Targeted Engineered Treg Approach for Treating B Cell Mediated Autoimmune Diseases”
Saturday, April 18 | 2:30 PM
GentiBio representatives will be available throughout the meeting to connect with colleagues across the immunology community and discuss the company’s expanding engineered Treg pipeline and clinical development programs.
About GNTI-122 and EngTreg Therapy
GNTI-122 is a novel, single-treatment, autologous engineered regulatory T cell (EngTreg) investigational therapy designed to restore immune tolerance by selectively suppressing autoreactive immune responses that drive type 1 diabetes. GNTI-122 cells are designed to migrate to the pancreas and associated lymphoid tissues and remain there to stably mitigate the immune response, preserving endogenous insulin production. GentiBio’s EngTreg platform builds on foundational discoveries in Treg biology, recognized by the 2025 Nobel Prize in Physiology or Medicine, and is designed to deliver targeted, durable immunomodulation with the goal of addressing the root cause of autoimmune disease.
About the POLARIS Study
Phase 1, Single Dose, Open-LAbel Study of GNTI-122 in Adults with Recently dIagnoSed Type 1 Diabetes (T1D) [POLARIS (NCT06919354)] is a clinical trial enrolling adults aged 18–45 years within 120 days of T1D diagnosis. The study evaluates the safety and tolerability of escalating doses of GNTI-122 and includes secondary and exploratory assessments of pharmacodynamic activity and clinical biomarkers, including measures of beta cell function. Participants are followed for up to 78 weeks. For more information, visit polarisstudy.com or ClinicalTrials.gov.
About GentiBio
GentiBio is a biotechnology company developing engineered regulatory T cell (EngTreg) therapies to restore immune tolerance and transform the treatment of autoimmune and inflammatory diseases. GentiBio’s EngTregs harness the underlying power of Tregs and are engineered for precision, durability, and scalable manufacture. GentiBio seeks to deliver disease modifying—and potentially curative—therapies for patients with significant unmet need. Learn more at http://www.gentibio.com.
Contact
Media email: Hatem.Heikal@gentibio.com
Clinical Email: Clinical_Ops@gentibio.com